Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)(2) components mediates reduced pulmonary inflammation in mice

Documenti analoghi

• Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naïve and Formalin-Inactivated RSV-Immunized BALB/c Mice
  di: Radu, Gertrud U., et al.
  Pubblicazione: (2010)
• Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
  di: Caidi, Hayat, et al.
  Pubblicazione: (2018)
• Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
  di: Caidi, Hayat, et al.
  Pubblicazione: (2012)
• Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice
  di: Rey, Gertrud U., et al.
  Pubblicazione: (2013)
• Neutralizing Anti-F Glycoprotein and Anti-Substance P Antibody Treatment Effectively Reduces Infection and Inflammation Associated with Respiratory Syncytial Virus Infection
  di: Haynes, Lia M., et al.
  Pubblicazione: (2002)